Abattis Bioceuticals Corp Stock Debt To Equity
| ATTBF Stock | USD 0.0001 0.00 0.00% |
Abattis Bioceuticals Corp fundamentals help investors to digest information that contributes to Abattis Bioceuticals' financial success or failures. It also enables traders to predict the movement of Abattis Pink Sheet. The fundamental analysis module provides a way to measure Abattis Bioceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Abattis Bioceuticals pink sheet.
Abattis |
Abattis Bioceuticals Corp Company Debt To Equity Analysis
Abattis Bioceuticals' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Abattis Bioceuticals Debt To Equity | 0.01 % |
Most of Abattis Bioceuticals' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Abattis Bioceuticals Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, Abattis Bioceuticals Corp has a Debt To Equity of 0.014%. This is 99.97% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The debt to equity for all United States stocks is 99.97% higher than that of the company.
Abattis Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Abattis Bioceuticals' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Abattis Bioceuticals could also be used in its relative valuation, which is a method of valuing Abattis Bioceuticals by comparing valuation metrics of similar companies.Abattis Bioceuticals is currently under evaluation in debt to equity category among its peers.
Abattis Fundamentals
| Return On Equity | -0.28 | |||
| Return On Asset | -0.16 | |||
| Operating Margin | (10.96) % | |||
| Current Valuation | 4.08 M | |||
| Shares Outstanding | 477.8 M | |||
| Shares Owned By Institutions | 0.02 % | |||
| Price To Earning | (5.83) X | |||
| Price To Book | 0.38 X | |||
| Price To Sales | 1.33 X | |||
| Revenue | 356.88 K | |||
| Gross Profit | 241.34 K | |||
| EBITDA | (2.9 M) | |||
| Net Income | (3.04 M) | |||
| Cash And Equivalents | 2.4 M | |||
| Total Debt | 150.86 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 0.73 X | |||
| Book Value Per Share | 0.02 X | |||
| Cash Flow From Operations | 9.41 M | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 32 | |||
| Beta | -60.6 | |||
| Market Capitalization | 473.03 K | |||
| Total Asset | 19.26 M | |||
| Retained Earnings | (10.13 M) | |||
| Working Capital | (588 K) | |||
| Current Asset | 260 K | |||
| Current Liabilities | 848 K | |||
| Z Score | 1.8 | |||
| Net Asset | 19.26 M |
About Abattis Bioceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Abattis Bioceuticals Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Abattis Bioceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Abattis Bioceuticals Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Abattis Pink Sheet
Abattis Bioceuticals financial ratios help investors to determine whether Abattis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Abattis with respect to the benefits of owning Abattis Bioceuticals security.